

## Biosynex lists on NYSE Alternext

**Paris, 25 March 2011** – NYSE Euronext today announced the listing of Biosynex, a provider of rapid medical diagnostic kits, on NYSE Alternext in Paris.

Founded in 2005, Biosynex develops, manufactures and markets membrane-based rapid diagnostic tests used in human medicine. Customers are clinical and research laboratories, as well as obstetrics and emergency services. The Biosynex portfolio includes 10 products, with a focus on testing in four areas: Epstein-Barr (EBV) serology, malaria screening, foetal membrane rupture, and detection of anti-tetanus immunity. The company has operations in Europe, the US, Africa and China. It has 17 employees.

The admission of Biosynex (ticker code: ALBIO) was by the listing of 495,000 existing shares and 398,200 new shares issued as part of a global offering<sup>1</sup>, including the full exercise of the Extension Option. The total amount raised through the global offering was €3.026 million.

The admission and issue price of Biosynex shares was set at €7.60 each. The company's market capitalization on the day of listing amounted to €6.79 million.

*"We are delighted with the successful listing of Biosynex on NYSE Alternext, and happy to contribute to the development of products that meet strong demand for fast, innovative testing,"* commented Ronald Kent, Group Executive Vice President and Head of International Listings at NYSE Euronext. *"Going public is a decision that will extend Biosynex's reach and accelerate its move into a fast-growing market."*

Thierry Paper, Chairman and Chief Executive Officer of Biosynex, added, *"Our successful listing on NYSE Alternext reflects the relevance and credibility of our strategy, along with investor interest in growth stocks that are both innovative and profit-oriented. We would like to thank the institutional and individual investors that have placed their trust in us and will be sharing in our strong growth. And we are very happy to enter a new stage in our development that will put our core products in pole position worldwide."*

In just over five years, €2.4 billion has been raised on NYSE Alternext, half of this through secondary issues, by 158 companies from countries including Belgium, Canada, China, France, Italy, Luxembourg, the Netherlands, Spain, the UK and the US. Their market capitalization totals €5.6 billion.

Euroland Finance is the Listing Sponsor of Biosynex.

---

<sup>1</sup> The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

**Contacts:**

**NYSE Euronext – Press contacts**

Caroline Tourrier: +33 (0)1 49 27 10 82

**Cap Value – Financial communications**

Gilles Broquelet: +33 (0)1 80 81 50 00

**Euroland Finance – Listing Sponsor**

Julia Bridger: +33 (0)1 44 70 20 84



**About NYSE Euronext**

NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets – the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca – represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: <http://www.nyx.com>.

**About Biosynex**

Biosynex was founded in 2005 by pharmacist/biologist Thierry Paper, now its Chairman and CEO. The company develops, manufactures and markets particularly innovative rapid diagnostic tests that improve patient care by generating test results both quickly and easily. Backed by its portfolio of core products, Biosynex is expanding rapidly on international markets, building on high-level scientific partnerships to expand its offering.